GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (TSX:CSCI) » Definitions » Forward PE Ratio

Cosciens Biopharma (TSX:CSCI) Forward PE Ratio : 0.00 (As of Mar. 23, 2025)


View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma Forward PE Ratio?

Cosciens Biopharma's Forward PE Ratio for today is 0.00.

Cosciens Biopharma's PE Ratio without NRI for today is 0.00.

Cosciens Biopharma's PE Ratio (TTM) for today is 0.00.


Cosciens Biopharma Forward PE Ratio Historical Data

The historical data trend for Cosciens Biopharma's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma Forward PE Ratio Chart

Cosciens Biopharma Annual Data
Trend
Forward PE Ratio

Cosciens Biopharma Quarterly Data
Forward PE Ratio

Competitive Comparison of Cosciens Biopharma's Forward PE Ratio

For the Biotechnology subindustry, Cosciens Biopharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Forward PE Ratio falls into.



Cosciens Biopharma Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Cosciens Biopharma  (TSX:CSCI) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Cosciens Biopharma Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.
Executives
Dennis Turpin Director
Gilles Gagnon Director